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ABSTRACT
Introduction: In-office phototherapy is an
effective treatment for many dermatologic
conditions, however, many patients are unable
to adhere to the rigorous travel and time
commitments sometimes needed. Tanning bed
facilities are nearly ubiquitous in modern
society and could represent a more convenient
means to obtain ultraviolet (UV) exposure when
office phototherapy is not feasible. The purpose
of this study was to review available evidence on
the use of tanning facilities as a treatment for
dermatologic conditions.
Methods: PubMed was searched on February
2015 for ‘‘tanning beds’’ and ‘‘phototherapy’’,
and with some dermatologic conditions
sensitive to UV light, including ‘‘psoriasis’’,
‘‘mycosis fungoides’’, ‘‘acne’’, ‘‘atopic
dermatitis’’ and ‘‘eczema’’. From there, further
articles were found using the reference sections
of the initial papers. A similar methodology was
used with the Google Scholar search engine.
Only articles in English and prospective studies
were included in this review.
Results: We found studies validating the use of
tanning facilities for psoriasis treatment. Use as
a treatment option for atopic dermatitis,
mycosis fungoides, acne, scleroderma, vitiligo,
and pruritus, as well as other UV sensitive
dermatoses, may also be beneficial. This study
is limited by the lack of double-blind, placebo-
controlled trials, long-term follow-up studies,
and meta-analyses for tanning facility use in
dermatologic phototherapy, and by the lack of
standardization of both tanning facilities and
exposure dosing.
Conclusion: Unsupervised sun exposure is a
standard recommendation for some patients to
obtain phototherapy. Selected use of
commercial tanning beds in the treatment of
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dermatologic conditions may be another useful
and effective treatment for those patients with
an inability to access office-based or home-
based phototherapy.
Keywords: Acne; Dermatitis; Eczema; Mycosis
fungoides; Phototherapy; Pruritus; Psoriasis;
Tanning beds
INTRODUCTION
Ultraviolet (UV) phototherapy is used for a
myriad of dermatologic conditions such as
psoriasis and mycosis fungoides (MF). UV
phototherapy is most commonly administered
in an office setting, with ideal treatment
typically consisting of several sessions per week.
While phototherapy is effective for many
conditions, the time and expense of this
treatment can be a burden and an obstacle [1].
Many patients live over one hundred miles from
a dermatologist or have other time and resource
limitations that make in-office phototherapy
inaccessible. Therefore, in-office phototherapy
may not be a pragmatic treatment option for
many patients who could potentially benefit
from it.
Unsupervised sun exposure is a standard
recommendation when in-office phototherapy
is not feasible [2]. Commercial tanning facilities
may offer another potential alternative means
to access phototherapy, being both
conveniently located and economically
feasible. This can provide access to
phototherapy to many patients who currently
find treatment with in-office phototherapy to
be cumbersome or impracticable. We examined
available evidence for the use of commercial
tanning facilities as a dermatologic treatment
modality in diseases such as atopic dermatitis,
acne, hand eczema, MF, vitiligo, and pruritus.
METHODS
Literature searches were done in PubMed in
February 2015 combining therapy descriptor
keywords, such as ‘‘tanning beds’’ and
‘‘phototherapy’’, with dermatologic conditions
known or believed to be sensitive to UV light,
including ‘‘psoriasis’’, ‘‘mycosis fungoides’’,
‘‘acne’’, and ‘‘atopic dermatitis’’/‘‘eczema’’. No
inclusion or exclusion dates were defined. From
there, further articles were found using the
reference sections of the initial papers. A similar
methodology was used with the Google Scholar
search engine. Additional information was
sought with targeted searches in both PubMed
and Google Scholar. In conditions that did not
have studies using commercial tanning beds, we
investigated the efficacy of UV radiation
overlapping with the emission spectrum of
tanning beds. Only articles in English and
prospective studies were included in this
review. This article is based on previously
conducted studies and does not involve any
new studies of human or animal subjects
performed by any of the authors.
RESULTS
Characteristics of Indoor Tanning Light
The light used during indoor tanning is poorly
defined. The US Food and Drug Administration
does not specify limits on the power of UV light
emissions, instead defining ‘‘irradiance ratio
limits’’, where the ratio of irradiance between
wavelengths of 200 and 260 nm to the
irradiance between wavelengths 260 and
320 nm should not exceed 0.003 at any
distance and direction from the source [3].
While in the US there are state and federal
regulations, according to a study performed in
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North Carolina, the extent to which
commercial tanning facilities comply is poor,
with only 1 out of 32 commercial tanning
establishments within complete compliance of
state and federal guidelines [4].
The wavelengths of UVA and UVB
irradiation from tanning beds are highly
variable; however, tanning beds as a whole
tend to emit primarily UVA irradiation. Rates of
UVB emissions range from 0.5% to 5.0% in
North Carolina tanning beds [4]. Another study
of North Carolina tanning beds found a wide
range of UVA irradiance, 17.7–674.0 W/m2 and
a UVB range of 0.12–0.82 W/m2 (2.11–14.00
minimal erythemal dose/h) [5].
Tanning beds analyzed in the UK between
2004 and 2005 showed tremendous variability
in spectral distribution of UV output, resulting
in the average erythemal irradiance ranging
from 0.02–0.93 W/m2, with an average of
0.41 W/m2 [6]. In a study conducted in 2008,
78 indoor tanning facilities from 6 regions
throughout Norway were characterized [7].
The average UVB irradiance was 0.194 W/m2
erythema-weighted dose (range 0.059–0.489
W/m2), and the average UVA irradiance was
0.156 W/m2 erythema-weighted dose (range
0.079–0.568 W/m2). Norway regulates indoor
tanning facilities, with both short-wave and
long-wave UV irradiance limits set at 0.15 W/
m2. Only 23.3% of tanning facilities were in
compliance with maximal irradiances for both
UVA and UVB spectra. Ninety-six percent of
tanning bed devices were approved models, but
only 74% of lamps in these tanning beds were
an approved type. The maximum erythema-
weighted UV irradiance varied by up to a factor
of 2 for the same tanning bed devices in
different facilities, due to the difference in
lamps used. Additionally, within each facility,
irradiance measures varied by up to a factor of
two, due to the different tanning bed devices
[7]. The variety of tanning bed devices and lack
of standardization of lamps within these devices
present a therapeutic hurdle to recommending
their use as a treatment for skin disease.
Efficacy of Tanning Beds
While different tanning beds emit variable
amounts of UVB and UVA (varying in both
the absolute flux and the ratio of UVB to UVA),
there is extensive in vitro evidence that both
UVA and UVB have anti-inflammatory effects
(Tables 1, 2).
Risks of Tanning
As with any UV light-based therapies, there are
potential risks of using tanning beds as
treatment (Table 3). There is a link between
artificial UV light exposure and an increased
risk of developing skin cancer. In 2006, a meta-
analysis showed an increased risk of developing
melanoma, squamous cell carcinoma (SCC),
and basal cell carcinoma (BCC) in patients
who have ever used a tanning bed compared
with those who have never tanned with
artificial UV light [8]. A particularly large
increase in melanoma risk was found when
comparing those who ever tanned before age
35 years to those who had never used an indoor
tanning device. A subsequent study found a
dose/response relationship between artificial
UV light exposure and increasing risk of
melanoma, with those having tanned 10 times
or fewer having only a 34% increased risk of
developing a melanoma, compared to 272% in
those patients who have used indoor tanning
beds over 100 times [9]. In a more recent study,
an association was found between age of first
tanning bed exposure and increased risk of
melanoma in patients with more than 10
tanning bed exposures [10]. A large
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prospective study found no association between
age range of most frequent tanning bed use and
risk of melanoma or SCC, but did find an even
greater risk of BCC in women who visited
tanning beds most frequently during their
high school and college years compared to
those who visited most frequently during age
25–35 years, both of which were greater than
the risk in women who had never used a
tanning bed [11]. This was further supported
by findings that a dose/response relationship
can be found between the risk of developing a
BCC and increasing numbers of tanning
sessions, hours spent indoor tanning, years
spent indoor tanning, number of burns at the
biopsy site, and number of burns associated
with indoor tanning [12]. This study also found
a strong relationship with artificial UV light
exposure and truncal BCCs, as compared to the
head and neck, indicating a possible increases
susceptibility of bodily areas that receive less
incidental solar irradiation [12]. Furthermore,




UVA Induces expression of HO-1, which catalyzes the degradation of heme to biliverdin and bilirubin, themselves
potent antioxidants, and to carbon monoxide, which suppresses proinﬂammatory cytokines. HO-1
activation may play a immunoprotective role in humans from increased IFN-c as well. Langerhans cell
counts are decreased in human epidermis after 4 weeks of UVA tanning bed exposure [60]
Blood CD3
? and CD4
? counts are reduced in patients after exposure to UVA dominant tanning bed
treatments [61]
UVB UVB depletes of LC, the major antigen-presenting cell of the skin, through migration of damaged LCs to
regional lymph nodes and through direct apoptosis. UVB exposed LCs preferential present antigens to Th2
and do not stimulate Th1. UVB irradiation induces T-suppressor and immunotolerant macrophages in the
epidermis [62]
Suppression of ICAM-1 expression by keratinocytes associated with a signiﬁcant increase in intracellular
thymine dimers in vivo with restoration of ICAM-1 expression via topical DNA repair enzyme [63]
Both CGRP is released from cutaneous nerves after xposure to UVR, increasing cAMP levels in T cells, inhibiting T
cell proliferation and inhibiting the production of IL-2 and expression of TNF-a, TNF-b and IFN-c.
CGRP also causes mast cells to degranulate and release TNF-a, which can interfere with APC’s ability to
initiate the inﬂammatory cascade [64]
The UV-induced mast cell degranulation releases the anti-inﬂammatory cytokine IL-10. UV irradiation
damages keratinocyte DNA, activating p53 and subsequently increasing the transcription of POMC, which
itself induces further production of IL-10 [65]
Stimulates HDMEC to produce a-melanocyte-stimulating hormone, inhibiting expression of the adhesion
molecules VCAM-1 and E-selectin, inhibiting the extravasation of leukocytes during inﬂammation [64]
PUVA Induces cell death by inducing DNA damage, initiating a delayed apoptotic cascade [66]
APC antigen-presenting cell, CGRP calcitonin gene-related peptide, HDMEC human dermal microvascular endothelial
cells, HO-1 heme oxygenase, ICAM-1 intracellular adhesion molecule 1, IFN Interferon, IL interleukin, LC langerhans cells,
POMC proopiomelanocortin, PUVA psoralen ultraviolet A, Th1 type 1 T cells, Th2 Type 2 T cells, TNF tumor necrosis
factor, UV ultraviolet, UVR ultraviolet radiation, VCAM-1 vascular cell adhesion molecule 1
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Table 2 Summary of evidence supporting commercial tanning beds or UV light in the treatment of selected dermatologic










Psoriasis Within-patient control supports both high and lower
percentage UVB output tanning bed light [18]
Ib
Clinical trial demonstrates more improvement in PASI
with increased UV light exposure [19]
IIb
Increased reduction in PASI score of unilateral side of
patients treated with UVA dominant light vs. the
contralateral side treated with dominantly visible light
[22]
IIa
Randomized controlled trial noted a 74% reduction in
PASI 75 scores in patients using home UVB vs. 70%
reduction in outpatient UVB [25]
IIb
Acne Experimental trial for blue light [67] and red–blue light
[68], and photodynamic therapy [27, 28] but no
direct evidence for ultraviolet light
Atopic
dermatitis
NB-UVA1, medium-dose UVA1, NB-UVB, and
combination UVA/UVB irradiation have







Hand eczema Oral methoxsalen UVA treatments three times per
week at home with a portable facial tanning unit was
found to be as effective as inpatient, biweekly
trioxsalen bath UVA treatments [38]
Ib
CTLC 4/4 Stage I/II CTCL plaques cleared with 120 J/cm2
max dose UVA1 and 3/4 cleared with 80 J/cm2 max
dose [40]
Treatment NB-UVB ranging from led to complete
remission in 76.4% of patients [39]
IIb
IIc
NB-UVB found to be effective in 6/8 patients with
Stage I CTCL [69]
IIb
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the World Health Organization characterizes
tanning beds as carcinogenic to humans,
therefore, caution should be exercised in
recommending tanning beds for treatment,
especially in those who are at risk for
developing melanoma or other skin cancers
[13]. While there is strong evidence supporting
association of tanning bed use and the
increased risk of skin cancer, some of this
association may not be causal in nature.
Tanning and Conditions Treated
by Phototherapy
Psoriasis
Assessing the evidence for commercial tanning
facilities as a treatment for psoriasis is
important as indoor tanning is already
commonly used by people as a psoriasis
treatment, perhaps the most frequently used
form of phototherapy for psoriasis. One center
reported that more than 50% of patients
presenting to their clinic had tried or were
currently treating their psoriasis with
commercial tanning sessions [14]. Another
survey found that 36% of patients reported
having tried commercial tanning beds as a
psoriasis treatment [15].
There may be concern that tanning beds that
emit primarily UVA would not be effective for
the treatment of psoriasis. While one study
Table 3 Risks and side effects associated with excess
ultraviolet light exposure [73]
Erythema Epidermal hyperplasia
Pruritus Dermal edema
Polymorphic light eruption Perivascular inﬂammation











Vitiligo PUVA [70], broadband and NB-UVB [42–45, 70, 71],
and excimer laser [72] with/without adjuvant










UVB light effective in 80–90% of patients with uremic
pruritus [54] and NB-UVB was also effective in




CTLC cutaneous T cell lymphoma, NB narrow band, PASI Psoriasis Area Severity Index, PUVA psoralen ultraviolet A, UV
ultraviolet
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found that UVA doses up to 30 J/cm2 were
ineffective for psoriasis, Parrish [16] found that
psoriatic plaques are responsive to
erythemogenic doses of either UVA or UVB
light [16, 17]. The ability of tanning beds to
treat psoriasis was compared on the basis of
their UVB output, one with a UVB output of
4.6% was compared to another with a lower
UVB output (0.7%) in a within-patient
comparison technique [18]. There were
marked and equivalent improvements in
Psoriasis Area Severity Index (PASI) scores from
baseline in patients treated unilaterally with
either lamp with 12 exposures to an equal
erythemal dose over a 4-week period. While
exposure to either UVA or UVB light can induce
clearance of psoriatic plaques, UVA requires
more energy (time 9 power) to reach
erythemogenic dosing [16].
The ability of a specific tanning bed using
the Bellarium S lamp (a commonly used
tanning bulb) to clear psoriatic plaques was
tested in a clinical trial [19]. Twenty patients
with psoriasis vulgaris were treated with three to
five tanning bed sessions per week for a 6-week
period. Sixteen patients had improvement in
their disease as measured by PASI and 17
patients as measured by the self-administered
PASI (SAPASI). The average reduction in the
PASI and SAPASI was 35.4% and 36.2%,
respectively, for all enrolled patients and
39.4% and 52.3%, respectively, in those
completing the 6-week study. A clear dose
response was observed, with greater
cumulative UV exposure associated with
greater disease improvement. The magnitude
of PASI reduction was modest compared to
recent studies of biologics, but the authors
commented that the improvement was
comparable to PASI reductions reported in
patients treated with betamethasone valerate,
calcipotriol, dithranol, and etretinate [20, 21].
Short-term side effects were minimal, including
mild phototoxic reactions in seven patients and
itching in three patients [15]. Long-term risks,
however, were not assessed. Overall, this study
demonstrated the efficacy and feasibility of
using commercial tanning beds in the
treatment of psoriasis, but as the tanning bed
treatments were administered in a well-
monitored medical setting, the findings may
not fully extrapolate to tanning in the
community setting.
A study assessing the effectiveness of a UVA
light-dominant commercial tanning unit
compared to visible light using each patient as
their own control demonstrated a slight, but
significant improvement in the PASI score, with
the difference coming from an improvement in
the erythema component of the PASI score [22].
One of the most effective treatments for
psoriasis is the combination of phototherapy
and oral retinoids [23]. Acitretin and tanning
bed UV exposure combination therapy has been
studied and is more effective than tanning
alone, with 83% of patients achieving
clearance or near clearance in a retrospective
review, and PASI scores demonstrating an
average reduction of 79% from baseline in a
prospective open-label trial of 17 patients [24].
Not only did many patients clear or experience
near clearing of the psoriasis, but in both the
retrospective review and prospective trial,
several patients were able to remain clear after
stopping acitretin and only using two
maintenance tanning bed light treatments per
week. This illustrates the potential for tanning
bed treatments as the only maintenance
therapy for patients who are currently clear of
their psoriasis [24].
Home UVB therapy is also a convenient
option for patients with psoriasis, although
not all patients have access to it. One
randomized, controlled study comparing
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home UVB to outpatient administered UVB
treatment demonstrated similar efficacy to
that of outpatient UVB therapy [25]. In this
study, median PASI scores decreased for patients
receiving home phototherapy 74%,
respectively, compared to a 70% decrease in
the outpatient phototherapy group.
Acne
Various light source therapies are either
currently used or under investigation for the
treatment of acne vulgaris, mainly pulsed dye
laser or photodynamic therapy [26–28]. While
the evidence for the use of tanning beds to treat
acne is limited, in a study of Swedish tanning
bed users, 34% believed that sunbathing in
natural light improved acne versus only 11% of
non-users, which suggests a potential use of
tanning beds as a possible adjuvant treatment
for acne [29]. However, we did not identify any
clinical trial supporting the use of tanning bed
UV light in the treatment of acne vulgaris.
Atopic Dermatitis
The prevalence of therapeutic use of tanning
beds in patients with atopic dermatitis has been
reported to be 66% [29]. This is not unexpected
as narrow band (NB) UVA1, medium-dose
UVA1, and combination UVA/UVB irradiation
have been successfully employed as treatments
for atopic dermatitis [30–32].
Daily exposure to high-dose UVA1 (130 J/
cm2) resulted in significant improvement of
study subjects’ atopic dermatitis [21]. UVA1
(60 J/cm2) is equally effective compared to
topical tacrolimus in treating atopic dermatitis
[33]. UVA/UVB treatment was also effective at
reducing clinical score [34]. NB-UVB as
monotherapy is also effective in treating
atopic dermatitis [35]. To our knowledge, no
studies have been done investigating the use of
tanning beds in atopic dermatitis, however, the
range of UV light sources demonstrated to be
effective in the treatment of atopic dermatitis
suggests that the use of tanning beds as a
treatment for atopic dermatitis may be
efficacious.
Hand Eczema
Psoralen UVA (PUVA) is highly effective in the
treatment of hand eczema [36, 37]. In an open-
label randomized controlled trial comparing
two established protocols, oral methoxsalen
UVA treatments three times per week at home
with a portable facial tanning unit were found
to be as effective as inpatient, biweekly
trioxsalen bath UVA treatments [38]. A 9 mW/
cm2 (90 W/m2) UVA facial tanning unit was
used; the power output of this device is far
below the average of 192.1 W/m2 found in the
North Carolina tanning bed study. Due to
commercial tanning beds having primarily
UVA irradiation, use of tanning beds with
psoralen may have a place in the out of office
treatment of chronic hand eczema, however,
care must be taken because of the risks of severe
burns. Concurrent use of tanning beds and
psoralen may be potentially used in hand
eczema due to the low body surface area
involved, as patients would only need to
expose their hands to the tanning bed
radiation. The application of psoralen to
extensive areas or systemic psoralen should
not be used with tanning beds, as the risks of
burns may be life threatening in these patients.
Cutaneous T Cell Lymphoma
Various phototherapeutic modalities are
currently used for MF. Treatment with NB-
UVB is effective for MF, leading to complete
remission in the majority of patients [39]. The
efficacy of five times weekly UVA1
phototherapy for the treatment of MF was also
investigated [40]. After 3 initial treatment
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sessions with standardized doses of 10, 20, and
40 J/cm2, symptoms were used to determine
future dosing, with all 4 patients clearing with
maximum doses of 120 J/cm2 UVA1 and 3 out
of 4 clearing with maximum doses of 80 J/cm2.
With minimal erythemal dosing of UVA light
noted to be 10–100 J/cm2 [16] commercial
tanning beds could be used to deliver
therapeutic doses of UVA light in the
treatment of cutaneous T cell lymphoma,
though we found no reported cases of this
therapeutic approach.
Vitiligo
Many UV-based therapies are employed when
treating vitiligo, including PUVA, NB-UVB
(both in office and home units) and excimer
laser, along with adjuvant treatments such as
topical calcineurin inhibitors and topical
corticosteroids [41–44]. One study found that
broadband UVB phototherapy was superior to
NB-UVB in treating vitiligo, which suggests that
tanning beds would also be effective [45]. Sun
exposure induces repigmentation of vitiligo
lesions during the summer in many patients
[46]. While there is a possibility of using
commercial tanning beds to deliver
therapeutic doses of UV light to patients with
vitiligo, we did not find clinical trials assessing
this potential use.
Pruritus
The pathophysiology of itch is still being
elucidated, and the mechanism by which UV
light reduces pruritus is not well defined. Given
the relative lack of penetration of UVB through
the epidermis, the effect of UVB is thought to be
through its action on epidermal keratinocytes
and Langerhans cells. The effects of UVA light
are generally believed to be dermal in origin,
affecting lymphocytes, mast cells, and
fibroblasts [47]. Dermal Schwann cells and
perineural cells degenerate after exposure to
UVA light as well [48].
UVB light has been successfully employed in
the treatment of uremic pruritus for decades.
Early studies demonstrated the efficacy of
broadband UVB, with 9 out of 10 patients
experiencing a significant reduction in pruritus
[49]. NB-UVB is also effective [50, 51]. There are
several theories on the mechanism of UVB light
in the treatment of uremic pruritus, including
UVB-induced reduction in skin phosphorus,
leading to decreased microprecipitation of
divalent cations with phosphorous in the skin
and UVB-induced mast cell apoptosis [52, 53].
There may be a systemic effect of UV on uremic
itch, as patients treated unilaterally with UVB
light report a reduction in pruritus on both
sides of their body [54].
HIV pruritus can be treated with either UVB or
PUVA [55, 56]. And while in vitro and animal
studies on the safety of UV light therapy raise
concerns about induction of viral replication,
these safety concerns have not shown up in vivo,
and reviews of the literature have endorsed UV
light therapy as safe in this setting [57, 58].
However, we found no data on the potential use
of commercial tanning beds in the treatment of
HIV-associated pruritus.
DISCUSSION
Many skin conditions are responsive to office
phototherapy, however, office phototherapy
can be expensive and inconvenient. Home
UVB therapy is a potential alternative. When
phototherapy is desired and office and home
UVB treatments are not feasible, indoor tanning
may be of benefit. There are certainly
limitations to this approach—imprecise
outputs of the lamps and beds, imprecise
spectral targeting of commercial tanning beds,
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administration by the patient or non-medical
staff, acute and long-term side effects—but
there are limitations to all treatment options.
Due to the significant risks of tanning beds and
the potential variability in dosing, practitioners
should exercise their clinical judgment in
recommending it to their patients. While
some patients may benefit, others may have
significant risk factors, such as a predisposition
to skin cancer, that would need to be taken into
account (along with the risks of other
treatments and the risk of suffering with no
treatment) when recommending treatment
options.
A significant concern for use of commercial
tanning facilities in phototherapy is their
considerable variability in emission make up
and dosing. Variability in exposure can be
reduced by selecting a single bed, with
additional caution/dose reduction when bulbs
are changed; doing so may provide more
predictable dosimetry than is obtainable with
sun exposure. For psoriasis treatment, 3–5
sessions per week for 6 weeks with 4.6% UVB
tanning lamps was effective (Table 4) [19]. The
length of the sessions was based upon self-
reported skin type and the manufacturer’s
suggestions for the particular bulb used in that
study. For patients on an oral retinoid, a starting
dose of 2–3 min with 1 min incremental
increases (30 min maximum), 5–7 times a
week was safe in a single study that used a
4.7% UVB output commercial tanning unit
(Table 5) [24]. Because of the variability
between different tanning beds, these data can
give only a limited reference point for dosing;
starting with a low dose and increasing slowly
as tolerated would be prudent.
Given the variability demonstrated in the
UV output of indoor tanning devices, we
recommend some practical safety tips
(Table 5). Patients should keep treatment time
the same if they have asymptomatic pinkness or
erythema of the skin and should be aware side
effects such as pain and/or blisters. Patients
with lighter skin types should exercise more
care as they are more susceptible to burns from
tanning compared to darker skinned
individuals. After about six times per week for
1 month, reassess for response to treatment.
This approach maximizes safety and allows for
increasing doses as tolerated.
This study is limited by the lack of double-
blind, placebo-controlled trials, long-term
follow-up studies and meta-analyses for
tanning facility use in dermatologic
phototherapy, and by the lack of
standardization of both tanning facilities and
exposure dosing. Furthermore, much of what is
extrapolated for the efficacy of tanning beds is
through methods which emit UV therapy that
overlaps with the UV emissions of tanning beds.
Commercial tanning beds have been
successfully used as a treatment modality for
patients with psoriasis, and show promise for
the treatment of many other dermatoses
Table 4 Fleischer et al. [19] exposure schedule for the use of tanning beds for psoriasis treatment
Skin type Exposure, min Sessions per week
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6
I 2 4 10 15 20 25 3–5
II 3 7 15 20 25 30 3–5
III 3 7 15 20 25 30 3–5
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(Table 2). The evidence for the use of
commercial tanning, with its clear dose–
response effect [18], is as strong as or stronger
than for sun exposure, which lacks
demonstration of a dose–response effect [59].
Moreover, dosimetry can be better controlled
with the use of indoor tanning when compared
to exposure to natural sunlight, which can vary
greatly based on geographical location, weather
conditions, and the time of day and year [59].
The National Psoriasis Foundation [2]
recommends natural sunlight as a potential
treatment for psoriasis. Considering this,
recommending the use of tanning beds as a
potential treatment may be just as reasonable.
CONCLUSIONS
While the use of tanning beds may not be right
for every patient, in some patients the benefits
of tanning beds as a source of UV therapy for
their dermatological disease may be beneficial.
Whether physicians recommend commercial
tanning bed use or not, patients are likely to
try it. In one study, nearly a third of male
patients with psoriasis and nearly half of female
patients with psoriasis reported having tried
tanning as a treatment [15]. Withholding
information on how to best use tanning may
not be in our patients’ best interest. While
tanning beds carry the possibility for significant
side effects, their benefits and risks should be
weighted just as with any treatment or
medication. Furthermore, the risks of
treatments that would be used as an
alternative to tanning beds should also be
considered, as many medications, such as
methotrexate, carry the risk of severe side
effects. Although there are significant risks
associated with tanning beds, completely
discounting its use may be a disservice to
patients who have poor access to in-office and
home phototherapy.
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